Table 4.
ORR for selected biomarker subgroups; modified full analysis set (N = 47).
| Gene | Patients, n | Responses, n | ORR, % (90% CI) |
|---|---|---|---|
| TP53a | |||
| Wild type | 2 | 0 | 0.0 (0.0, 77.6) |
| Mutant | 34 | 9 | 26.5 (14.6, 41.6) |
| ARID1A | |||
| Wild type | 34 | 9 | 26.5 (14.6, 41.6) |
| Mutant | 2 | 0 | 0.0 (0.0, 77.6) |
| ATM | |||
| Wild type | 31 | 8 | 25.8 (13.5, 41.8) |
| Mutant | 5 | 1 | 20.0 (1.0, 65.7) |
| Germline BRCA1/2 | |||
| Wild type | 31 | 7 | 22.6 (11.1, 38.3) |
| Mutant | 5 | 2 | 40.0 (7.6, 81.1) |
| Basal subtypeb | |||
| Yes | 36 | 9 | 25.0 (13.7, 39.6) |
ARID1A AT-rich interaction domain 1A, ATM ataxia-telangiectasia-mutated, BRCA1/2 breast cancer gene 1/2, CI confidence interval, ORR overall response rate, PAM50 Prediction Analysis of Microarray 50, TP53 tumor protein 53.
aOnly patients with biomarker status determined by FoundationOne® CDx next-generation sequencing were reported.
bBasal subtype was determined via PAM50 analysis (Prosigna) and was performed retrospectively.